---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-131037"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2024-12-23T23:59:59+00:00"
generated_at: "2026-05-28T23:48:09.966376+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Zura Bio launches Phase 2 TibuSURE study of tibulizumab in systemic sclerosis

## Summary
- TibuSURE is a global Phase 2 double-blind, placebo-controlled trial in ~80 adults with early diffuse cutaneous systemic sclerosis.
- First clinical trial to target both BAFF and IL-17 pathways in SSC, using dual-antagonist antibody tibulizumab.
- Primary endpoint is modified Rodnan Skin Score; key endpoints include lung function (qHRCT, FVC) and physical function (HAQ-DI, rCRISS).
- Study includes 24-week efficacy period followed by a 28-week open-label extension.
- First clinical site has been initiated; results expected to inform further development.

## SEC filing metadata
- accession: 0001104659-24-131037
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2024-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465924131037/0001104659-24-131037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465924131037/tm2431378d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-131037
- JSON: https://secwatch.observer/filing/0001104659-24-131037.json
- Plain text: https://secwatch.observer/filing/0001104659-24-131037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.